European Pharmaceutical Review

DECEMBER 1, 2023

During CPHI Barcelona, EPR Editor Caroline Peachey asked Anil Kane, Global Head of Technical & Scientific Affairs, Pharma Services, at Thermo Fisher Scientific about the dynamic landscape of pharmaceutical drug development. What are the trends affecting drug development today?

Drug Development 98

Drug Development Dosage Diabetes Process Improvement 98

Syner-G

SEPTEMBER 15, 2023

Both processes are evolving to enhance product development and output. Upstream processing advancements encompass fed-batch processes , improved cell culture media, advanced feeding strategies, and tailored bioreactor control.

Drug Development 59

Drug Development Documentation Process Improvement Compounding 59

European Pharmaceutical Review

FEBRUARY 20, 2024

Other key influences helping the upstream bioprocessing market expand include drug development, antibody manufacturing, as well as a higher need for cell therapy research.

Process Improvement 98

Process Improvement Biosimilars Drug Development 98

Drug Patent Watch

DECEMBER 12, 2024

Understanding the Pharmaceutical Market Dynamics The pharmaceutical industry is a complex ecosystem where branded drugs and generics coexist, each playing a vital role in patient care and market dynamics. Branded drugs, developed through extensive research and clinical trials, often enjoy patent protection for a limited period.

Pharmaceutical Companies 96

Pharmaceutical Companies Pharmaceutical Companies Biosimilars Drug Development 96

PharmaState Academy

OCTOBER 20, 2023

a) Maximizing Profits through maximum patient's care b) Putting Patients First c) Regulatory Compliance and patient outcome d) Internal Processes improvement to improve patient's health outcomes 5 / 20 How can patient-centric marketing contribute to better healthcare outcomes?

Dosage 59

Dosage Pharmaceutical Companies Pharmaceutical Companies Process Improvement 59

European Pharmaceutical Review

NOVEMBER 9, 2023

Following her presentation on age-related disease at BioFuture 2023, Executive Vice President of Drug Development for MyMD Pharmaceuticals ® , Jenna Brager, shares with EPR why the company’s next-generation tumour necrosis factor (TNF)-alpha inhibitor has potential in inflammatory and autoimmune disorders.

Drug Development 115

Drug Development Immunity Immunization Pharmaceutical Companies 115

European Pharmaceutical Review

MAY 29, 2023

Recently, the European Medicines Agency (EMA) took the lead in pushing for process improvements using technologies already established in other manufacturing sectors. Despite this, only 13 nanomedicines had been approved by the US Food and Drug Administration (FDA) before 2015. Yet in 2021, 100 nanomedicines had been marketed.

Process Improvement 95

Process Improvement Packaging Vaccines Drug Development 95